FLoRA Replication Atlas › Browse

Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia

Mark A. Dawson, Rab K. Prinjha, Antje Dittmann, George Giotopoulos, Marcus Bantscheff, Wai-In Chan, Samuel C. Robson, Chun-wa Chung, Carsten Hopf, Mikhail M. Savitski, Carola Huthmacher, Emma Gudgin, Dave Lugo, Soren Beinke, Trevor D. Chapman, Emma J. Roberts, Peter E. Soden, Kurt R. Auger, Olivier Mirguet, Konstanze Doehner, Ruud Delwel, Alan K. Burnett, Phillip Jeffrey, Gerard Drewes, Kevin Lee, Brian J. P. Huntly, Tony Kouzarides

Nature, 2011. DOI 10.1038/nature10509

Has this study been replicated?

The atlas records 1 replication of this study. Recorded outcomes: 1 mixed.

Replications

• Replication Study: Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia, Shan et al. (2017). Outcome recorded: mixed. We found treatment of MLL-fusion leukaemia cells (MV4;11 cell line) with the BET bromodomain inhibitor I-BET151 resulted in selective growth inhibition View paper

Other studies in the atlas

• Replication Study: Inhibition of BET recruitment to chromatin as an effective treatment f…
• Systematic mutation screening and association study of the A1 and A2a adenosine receptor …
• Evidence for Genetic Linkage Between a Polymorphism in the Adenosine 2A Receptor and Pani…
• BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
• Replication Study: BET bromodomain inhibition as a therapeutic strategy to target c-Myc
• A Polymorphism in CALHM1 Influences Ca2+ Homeostasis, Aβ Levels, and Alzheimer's Disease …

Failed replications · Successful replications · All browse pages